US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology to jointly establish a cell therapy process development platform laboratory. The collaboration aims to advance innovations in cell therapy, although no financial details were disclosed.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a global leader in providing comprehensive solutions for medical technology products. The company specializes in blood components, therapeutic plasma separation and replacement, and cell therapy technology, offering cutting-edge services to healthcare providers worldwide.
EurekaBio’s Contributions
EurekaBio, a pioneer in the research and development of cell and gene therapy, brings its expertise in fully enclosed automated cell processing systems to the partnership. The company’s CellSep PRO and CellSep MAX systems are designed to enhance the efficiency and safety of cell processing, making them valuable assets in the development of innovative cell therapies.
Significance of the Partnership
This collaboration between Terumo Blood and Cell Technologies and EurekaBio is expected to accelerate the development of new cell therapy processes and technologies. By combining their strengths, the two companies aim to drive advancements in the field of regenerative medicine and improve patient outcomes.-Fineline Info & Tech
